- Scleroderma Therapeutics, also known as biotherapy or immunotherapy, uses living organisms or their components to treat diseases. These therapies have shown significant efficacy in managing cancer, autoimmune disorders, and genetic diseases due to their targeted action and reduced systemic side effects
- The demand for Scleroderma Therapeutics is significantly driven by rising incidences of cancer and autoimmune disorders, expanding approvals of biosimilars, and international investments in biotechnology innovation
- India is expected to dominate the Asia-Pacific Scleroderma Therapeutics market due to national rare disease programs, autoimmune disorder registries, and high treatment demand in systemic sclerosis.
- South Korea is expected to witness the highest CAGR in the Scleroderma Therapeutics market due to its growing biologics pipeline, clinical trial capacity, and government-backed healthcare innovation.
- Immunosuppressants segment is expected to hold the largest share of 42.5%, due to its widespread use in managing skin fibrosis and systemic complications. Expanding use of corticosteroids and methotrexate-based therapies is fueling demand in primary care settings.
